BTIG Reiterates Buy Rating on Ideaya Biosciences (IDYA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to BTIG Reiterates Buy Rating on Ideaya Biosciences (IDYA)
September 24, 2024 6:14 AM EDT
RBC Capital analyst Gregory Renza reiterated an Outperform rating and $61.00 price target on Ideaya Biosciences (NASDAQ: IDYA).
The analyst comments "Our key takeaway from IDYA's call this morning is a more refined blueprint for daro's regulatory path with positive ph.II data and the... More
September 23, 2024 4:34 PM EDT
Citi analyst Yigal Nochomovitz reiterated a Buy rating and $58.00 price target on Ideaya Biosciences (NASDAQ: IDYA).
The analyst comments "The Ph2 neoadjuvant UM data (including the prior IST) were in-line with our expectations for very substantial efficacy reflecting a 61% eye preservation rate among... More
September 23, 2024 3:48 PM EDT
Goldman Sachs analyst Corinne Jenkins raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $48.00 (from $47.00) while maintaining a Buy rating.
The analyst comments "DYA announced interim results from an ongoing Ph2 company-sponsored and investigator-sponsored study of darovasertib (daro) in neoadjuvant uveal melanoma (UM). Per the update, 49% (N=49) of patients achieved tumor shrinkage of 30%, while 61% (N=31) in the enucleation-evaluable cohort achieved eye preservation.... More
September 23, 2024 3:45 PM EDT
Stifel analyst Ben Burnett lowered the price target on Ideaya Biosciences (NASDAQ: IDYA) to $66.00 (from $68.00) while maintaining a Buy rating.
The analyst comments "We think the clinical data for darovasertib in the neoadjuvant setting are good, but that the stock... More
September 23, 2024 6:07 AM EDT
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced positive interim Phase 2 clinical trial data for darovasertib in neoadjuvant uveal melanoma (UM) and a successful FDA Type C meeting on registrational trial design for regulatory approval in neoadjuvant UM.
"Darovasertib has demonstrated compelling preliminary clinical efficacy and a favorable AE profile in the neoadjuvant UM setting, with approximately 49% of patients demonstrating greater than 30% tumor shrinkage and importantly approximately 61% eye preservation rate for enucleation... More
